1 articles with this tag
NRG Therapeutics secured £50 million in Series B funding, led by SV Health Investors’ Dementia Discovery Fund. This investment will advance mitochondrial-targeting treatments for neurodegenerative diseases. The company aims to transition its pipeline, including lead candidate NRG5051 for ALS and Parkinson's, into...
